These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19369677)

  • 21. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats.
    Aspenberg P; Wermelin K; Tengwall P; Fahlgren A
    Acta Orthop; 2008 Feb; 79(1):111-5. PubMed ID: 18283582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of bisphosphonate use for the dentist: an introduction.
    Kurtzman GM; Silverstein LH; Peden J; Shatz PC
    Dent Today; 2006 Jun; 25(6):80, 82-5; quiz 85. PubMed ID: 16792113
    [No Abstract]   [Full Text] [Related]  

  • 23. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bisphosphonates and osteonecrosis of the jaw].
    Saussez S; Filleul O; Loeb I
    Rev Stomatol Chir Maxillofac; 2008 Dec; 109(6):367-73. PubMed ID: 19013624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
    Armamento-Villareal R; Napoli N; Panwar V; Novack D
    N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
    Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
    Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sympathectomy, which induces membranous bone remodeling, has no effect on endochondral long bone remodeling in vivo.
    Sherman BE; Chole RA
    J Bone Miner Res; 2000 Jul; 15(7):1354-60. PubMed ID: 10893684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.
    Freiberger JJ
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):96-106. PubMed ID: 19371820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.
    Allen MR; Follet H; Khurana M; Sato M; Burr DB
    Calcif Tissue Int; 2006 Oct; 79(4):255-61. PubMed ID: 17033724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of bisphosphonate-associated osteonecrosis of the jaws and its management.
    Lam DK; Sándor GK; Holmes HI; Evans AW; Clokie CM
    J Can Dent Assoc; 2007 Jun; 73(5):417-22. PubMed ID: 17555652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warning: bisphosphonates and osteochemonecrosis of the jaws.
    Flint SR; Sharkey S; Galvin S
    J Ir Dent Assoc; 2006; 52(2):79-83. PubMed ID: 16989369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
    Kim MH; Shim KS; Kim SH
    Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microdamage and bone strength.
    Burr D
    Osteoporos Int; 2003 Sep; 14 Suppl 5():S67-72. PubMed ID: 14504709
    [No Abstract]   [Full Text] [Related]  

  • 39. Osteoclast inhibitors: a multifaceted tool in the management of breast cancer.
    Morikawa A; Van Poznak C
    Oncology (Williston Park); 2015 Jan; 29(1):39-42. PubMed ID: 25595285
    [No Abstract]   [Full Text] [Related]  

  • 40. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges.
    Jain N; Weinstein RS
    Nat Rev Rheumatol; 2009 Jun; 5(6):341-6. PubMed ID: 19491914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.